News Solasia Pharma K.K.

Equities

4597

JP3436500007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 EDT			5-day change	1st Jan Change
26 ^JPY	+4.00%		+4.00%	-42.22%

03-04	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI
02-16	Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	03-19	AQ
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	03-03	CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	02-15	CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited	02-14	CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	12-28	CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains	11-13	MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	11-13	CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index	23-09-18	CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-10	CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	23-05-15	CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe	23-03-21	MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program	23-03-20	CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023	23-02-14	CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study	22-11-27	MT
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-25	CI
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.	22-11-21	CI
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-14	CI
Solasia Announces Summary of SP-04 PledOx Development Status	22-09-05	CI
Solasia Launches Anticancer Injection Darvias	22-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Solasia Pharma K.K.

Equities

4597

JP3436500007

Summary

Filters